9776 — Sapporo Clinical Laboratory Balance Sheet
0.000.00%
- ¥6bn
- ¥5bn
- ¥20bn
- 85
- 72
- 86
- 96
Annual balance sheet for Sapporo Clinical Laboratory, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2,361 | 2,991 | 3,664 | 3,976 | 2,941 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,749 | 2,995 | 2,924 | 2,919 | 2,872 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,913 | 7,230 | 7,311 | 7,697 | 6,636 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7,758 | 8,128 | 8,449 | 8,191 | 8,906 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 14,511 | 16,149 | 16,521 | 16,681 | 16,451 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,106 | 3,282 | 3,257 | 3,307 | 3,121 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5,239 | 6,035 | 5,936 | 5,744 | 5,297 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 9,272 | 10,114 | 10,585 | 10,937 | 11,154 |
| Total Liabilities & Shareholders' Equity | 14,511 | 16,149 | 16,521 | 16,681 | 16,451 |
| Total Common Shares Outstanding |